News

AstraZeneca’s Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has been approved in the US as treatment for adult patients with…
Read More...

Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and…
Read More...

Charles River Laboratories International, Inc. and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany,  announced a plasmid DNA and retrovirus vector…
Read More...

BeiGene, a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its…
Read More...

AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in…
Read More...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD)…
Read More...

AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D)…
Read More...

Flagship Pioneering and ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, announced a…
Read More...

IQVIA announced the launch of One Home for Sites, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site…
Read More...

GSK plc announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics,…
Read More...

Cycle Pharmaceuticals Ltd, a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, today confirmed that it made a proposal to…
Read More...

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions,…
Read More...

QIAGEN announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several…
Read More...

Alphamab Oncology announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and collaboration…
Read More...

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer,…
Read More...

AbbVie announced that RINVOQ (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic…
Read More...

Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of PREZCOBIX…
Read More...

AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation…
Read More...

Quince Therapeutics, Inc., a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational, oral…
Read More...